Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

26.14USD
20 Jul 2018
Change (% chg)

$0.14 (+0.54%)
Prev Close
$26.00
Open
$26.06
Day's High
$26.26
Day's Low
$25.92
Volume
355,588
Avg. Vol
777,874
52-wk High
$27.32
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Immunomedics Announces Proposed Public Offering Of Common Stock
Monday, 11 Jun 2018 04:13pm EDT 

June 11 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.IMMUNOMEDICS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $275 MILLION OF SHARES OF ITS COMMON STOCK.IMMUNOMEDICS - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING FOR ACCELERATION OF CLINICAL DEVELOPMENT PROGRAM OF SACITUZUMAB GOVITECAN.  Full Article

Seattle Genetics Cuts Stake In Immunomedics To 4.9 Pct As From 7.3 Pct
Tuesday, 5 Jun 2018 04:40pm EDT 

June 5 (Reuters) - Immunomedics Inc ::SEATTLE GENETICS INC CUTS STAKE IN IMMUNOMEDICS INC TO 4.9 PERCENT AS OF JUNE 4, 2018 FROM 7.3 PERCENT AS OF DECEMBER 5, 2017 - SEC FILING.  Full Article

Immunomedics Q2 Loss Per Share $0.02
Thursday, 8 Feb 2018 04:15pm EST 

Feb 8 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.02.Q2 REVENUE ROSE 55 PERCENT TO $600,000.  Full Article

Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE.IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020.  Full Article

Immunomedics announces first quarter fiscal results
Thursday, 9 Nov 2017 04:10pm EST 

Nov 9 (Reuters) - Immunomedics Inc :Immunomedics announces first quarter fiscal 2018 results and provides corporate update.Q1 loss per share $0.97.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Immunomedics Inc - qtrly ‍total revenue was $0.7 million for both quarters ended September 30, 2017 and September 30, 2016​.  Full Article

Immunomedics to exchange about $80 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock
Friday, 15 Sep 2017 08:01am EDT 

Sept 15 (Reuters) - Immunomedics Inc :Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock.Immunomedics- To exchange about $80.0 mln of notes, for about 14.1 million newly issued shares of co's stock plus additional number of newly issued shares.Immunomedics- upon completion, aggregate principal amount of co's 4.75 pct Convertible Senior Notes due 2020 is to be reduced to about $20.0 mln.  Full Article

Immunomedics reports Q4 loss per share $0.48
Wednesday, 16 Aug 2017 04:00pm EDT 

Aug 16 (Reuters) - Immunomedics Inc :Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline.Q4 revenue fell 33 percent to $600,000.Q4 revenue view $2.3 million -- Thomson Reuters I/B/E/S.Q4 loss per share $0.48.Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Immunomedics Inc - ‍cash, cash equivalents, and marketable securities totaled $154.9 million as of june 30, 2017​.Immunomedics Inc - ‍company expects to present final results of IMMU-132 in mtnbc that will form basis of bla submission later this year​.Immunomedics Inc - ‍believe that current financial resources are sufficient to support operations through september 2018​.  Full Article

Immunomedics, Covance enter into master services agreement
Friday, 4 Aug 2017 04:12pm EDT 

Aug 4 (Reuters) - Immunomedics Inc ::Immunomedics Inc says ‍on July 31, co and Covance Inc entered into a master services agreement - SEC filing​.Immunomedics Inc - simultaneous with execution of agreement, covance and company executed a first work order with an effective date of july 31, 2017.Immunomedics - pursuant to terms of agreement, Covance to provide clinical services for clinical study or studies to co​.Immunomedics - under work order, co engaged Covance as clinical research organization to perform services in co's phase 3 clinical trial of sacituzumab govitecan.  Full Article

Immunomedics files for offering of 34.8 mln shares of common stock by selling stockholders
Monday, 31 Jul 2017 06:13pm EDT 

July 31 (Reuters) - Immunomedics Inc :Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing.Immunomedics inc says will not receive any of proceeds from sale of common stock by the selling stockholders.  Full Article

Immunomedics files for 34.8 mln shares of co's common stock
Monday, 31 Jul 2017 06:07pm EDT 

July 31 (Reuters) - Immunomedics Inc -:Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing.Immunomedics Inc says will not receive any of proceeds from sale of common stock by the selling stockholders.  Full Article

BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA

* IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION